US Stock MarketDetailed Quotes

PALI Palisade Bio

Watchlist
  • 2.4500
  • +0.0100+0.41%
Trading Nov 21 11:21 ET
3.26MMarket Cap-184P/E (TTM)
Intraday
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    Jaguar8
    Jaguar8
    3 hours ago
    NEWS
    $Palisade Bio (PALI.US)$
    Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)
    Data to be presented at the 8th Annual Antifibrotic Drug Development (AFDD) Summit
    PALI-2108 may offer a solution for fibrostenotic Crohn's disease by enhancing efficacy, safety, and therapeutic potential compared to traditional treatments
    Carlsbad, CA, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, a clinical-stag...
    Jaguar8
    Jaguar8
    Nov 12 07:47
    NEWS ER
    $Palisade Bio (PALI.US)$
    Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108
    Positive
    Initiated Phase 1 clinical trial with patient enrollment and dosing for PALI-2108
    Received European patent notice for PALI-2108 and PALI-1908
    Completed first GMP batch of PALI-2108 drug substance
    Successfully demonstrated ex vivo bioactivation in clinical studies
    Negative
    None.
    Jaguar8
    Jaguar8
    Oct 31 07:31
    NEWS
    $Palisade Bio (PALI.US)$
    Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis
    Palisade Bio (NASDAQ: PALI) has presented positive data from two ex vivo translational studies of PALI-2108, their colon-specific PDE4 inhibitor prodrug for ulcerative colitis treatment. The studies demonstrated successful bioactivation in stool samples and significant TNFα inhibition in whole blood. PALI-2108achieved a 90.1% conversion rat...
    Jaguar8
    Jaguar8
    Sep 25 07:02
    NEWS
    $Palisade Bio (PALI.US)$
    Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis
    Palisade Bio (Nasdaq: PALI) has made significant progress towards launching its Phase 1 human clinical study for PALI-2108, a locally activated PDE4 inhibitor prodrug for treating ulcerative colitis (UC). The company has:
    1. Completed nonclinical safety and toxicity studies
    2. Finalized Phase 1 clinical trial desi...
Read more

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data